SBC Medical Group Holdings Inc. (NASDAQ: SBC), a Japanese operator of aesthetic medical clinics, is making its first major move into the U.S. market through a strategic investment in OrangeTwist, a medspa chain with 24 locations across six states. The partnership, announced late last month, combines SBC's operational expertise and funding with OrangeTwist's advanced management system and non-invasive treatment offerings, targeting the growing demand for cosmetic aesthetics.
The medical aesthetics industry is projected to grow from $34 billion to $48 billion by 2030, driven by aging populations and preference for non-surgical treatments like injectables and laser therapies. SBC estimates that its collaboration with OrangeTwist will address "white space" in underserved U.S. markets, allowing the companies to establish first-mover advantages before competitors enter. Stephen Rodgers, global head of planning and strategy at SBC Medical, told Benzinga that the company seeks local partnerships aligned with its mission, rather than replicating its Japanese model directly. "As part of SBC’s global expansion, we are working hard to find local partnerships," Rodgers said in an interview with Benzinga.
Beyond the U.S., SBC is expanding in Japan and Southeast Asia, leveraging its proven business model to provide management services, staff training, and equipment pricing to partner clinics. The company's strategy rests on three pillars: partnering with scalable regional operators, deploying operational efficiencies, and securing first-mover advantages. The longevity industry, valued at approximately $85 billion in 2025 and expected to surpass $120 billion by 2030, also presents opportunities. According to Gabelli Research, North America accounts for 30% of the global anti-aging market, while Asia shows robust growth from beauty-conscious consumers.
SBC Medical's global network includes 258 affiliated clinics managing over six million patient visits annually. The company aims to standardize services across Japan, Thailand, and Singapore, ensuring consistent quality and pricing. By combining resources with OrangeTwist, SBC plans to jointly develop branded products and sell existing products in each other's spas. The partnership also includes institutional shareholders Hildred Capital and Athyrium Capital, which have longstanding investments in OrangeTwist.
As the 2026 longevity industry shifts from extending lifespan to enhancing "healthspan" through personalized, preventative solutions, SBC is positioning itself to offer AI-powered diagnostics, GLP-1 weight-loss drugs, and regenerative therapies. The company's expansion strategy reflects a broader trend in medical aesthetics, where non-invasive treatments are preferred for their minimal risk and downtime. To learn more about SBC Medical, click here.
This content was originally published on Benzinga.
